Genentech, its management and its founders are regularly recognized as leaders in the biotechnology industry. Genentech also receives recognition and awards for its overall performance as a company, its workplace culture, its contributions to the community and its patient advocacy. Below are some of Genentech's recent achievements.
|
On January 21, 2010, FORTUNE magazine named Genentech to its "100 Best Companies to Work For" list for the 12th consecutive year. In selecting the "100 Best Companies to Work For," FORTUNE relies on two sources: the opinions of the company's own employees and a "culture audit" of the programs and practices at each company. The former is deemed most important, with two-thirds of the total score coming from employee responses to a survey created by the Great Place to Work Institute. The remaining one-third of the score comes from FORTUNE's evaluation of each company's answers to questions about pay, benefits, hiring, communication, culture and diversity. The most important considerations for this year's list were whether companies are hiring and the ways in which companies are helping their employees weather the recession. Genentech is the only biotech/pharmaceutical company since 2000 to be ranked among the top 20.
|
|
|
Back to Top 
|
On October 2, 2009, Genentech was named "top employer in the biopharmaceutical industry" by Science magazine. Science's annual survey of Top Employers polls employees in the biotechnology, biopharmaceutical, pharmaceutical and related industries. Respondents are asked to rate companies based on 23 characteristics, including financial strength, easy adaptation to change and a research-driven environment. This is the eighth year Genentech has appeared on the list and the seventh number one ranking for the company.
|
|
|
Back to Top
|
On September 24, 2008, Working Mother magazine named Genentech one of the "100 Best Companies for Working Mothers." The list identifies companies who are "using company-wide benefits and programs to ensure the retention and advancement of working mothers." For this year's 100 Best, the magazine gave particular weight to family-friendly programs, flexibility, leave policies and benefits for part-timers. In compiling the list, the magazine's editors assessed work/life programs including: workforce profile; compensation, child care; flexibility; time off and leaves; family-friendly programs; and company culture. This is the 16th year Genentech has appeared on the list.
|
|
|
Back to Top
|
In May 2009, the San Francisco Business Times named Genentech number one on its list of the "Best Places to Work in the Bay Area." The ranking was decided largely on the basis of employee feedback via an online survey. Genentech was in the "largest employers" category, defined as having more than 1,501 employees. This is the fifth year that Genentech employees have participated in the survey, and the company has placed among the top five in the "largest employers" category each time.
|
|
|
Back to Top
|
In May 2009, FORTUNE magazine ranked Genentech number 32 on its list of "100 Top MBA Employers." The ranking is based on a survey by Universum research firm that asked 6,207 students (2,507 women, 3,680 men) at 53 top business schools nationwide where they'd most like to work. The company is up nine spots from its 2008 ranking of 41. This is the fifth time Genentech has appeared on the list.
|
|
|
Back to Top
|
In June 2009, Computerworld ranked Genentech number two in the large company category on its "100 Best Places to Work in IT" list. Genentech was recognized specifically for its personal leadership development programs designed to offer benefits that extend beyond the workplace and help create a better quality of life both at home and at work. This is the second year that the company has appeared on the list.
|
|
|
Back to Top
|
On March 3, 2008, FORTUNE magazine named Genentech number one in the Pharmaceuticals category on its 2008 list of "America's Most Admired" companies. To compile the list, FORTUNE asked executives, directors and securities analysts to rate the largest companies within their industries based on innovation, people management, use of corporate assets, social responsibility, quality of management, financial soundness, long-term investment and product/services quality. This is the third year Genentech has qualified for the list, and the second year in a row the company has ranked number one. |
|
|
Back to Top
|
In May 2008, Barron's magazine named Genentech number 41 on its annual "500 Best American Companies" list. For the 2008 Barron's 500 list, four equally weighted measures were used to grade and rank the largest companies in the United States and Canada. Calculations incorporate stock performance, the median cash-flow return on investment (CFROI), CFROI in the latest fiscal year compared to the three-year historical median, and sales growth over the latest fiscal year. Genentech is up from a number 42 ranking last year, and in 2008 it is the top ranking biotech/pharmaceutical company on the list.
|
|
|
Back to Top
|
In its January 2008 issue, Forbes magazine named Genentech to its "400 Best Big Companies in America" list in the Drugs and Biotechnology category. Qualified companies are ranked for financial performance against their industry peers on five-year and 12-month sales and earnings growth and total return to shareholders. Ranking items include consensus forecasts for long-term earnings growth and debt-to-capital ratios. This is the fifth year Genentech has appeared on the list.
|
|
|
Back to Top
|
In its September 2008 issue, Barron's named Genentech to its "World's Largest Most Respected Companies" list. The list is based on investor perception of the world's largest 100 companies based on stock-market capitalization. Barron's creates the list by asking institutional money managers to indicate the degree of respect, or lack thereof, they had for the world's largest companies as measured by market value. This year Genentech ranked number 16 on the list.
|
|
|
Back to Top
|
In May 2007, Genentech was ranked number 23 overall and number two in the healthcare industry on BusinessWeek magazine's "100 Most Innovative Companies" list. The Most Innovative Companies list is based on a senior management survey on innovation that is distributed to executives worldwide. The companies that made this year's list "are working to build organizations that are capable of sustained innovation."
|
|
|
Back to Top
|
In April 2007, Wired included Genentech at number three on its "Wired 40" list. The list consists of companies that are "masters of innovation and technology, global thinkers that dominate their industries and point the way to the future." To land a spot on the list, a business also needs the "X-factor" — a hunger for new ideas and an impatience to put them into practice. This is the fourth year Genentech has made the list, and the company is up from a number four ranking last year.
|
|
|
Back to Top
|
In October 2009, Genentech was selected as the world's most admired biotechnology company by MedAd News. MedAd News' Most Admired Companies list is based on a readership survey. Participants vote for three choices from among the top 25 pharmaceutical, top 25 biotechnology, and top 25 specialty independent and publicly traded companies based on worldwide 2008 revenue. This is the sixth year Genentech has ranked number one in the Biotechnology category.
|
|
|
Back to Top
|
In May 2007, Business 2.0 included Genentech at number 71 on its "100 Fastest Growing Tech Companies" list. To select the B2 100, the magazine screened more than 2,000 tech companies. The 100 chosen companies were ranked using the following financial criteria: growth in revenue, profit and operating cash flow during the past three years, and the 12-month stock return as of December 31, 2006. This is the fourth year Genentech has made the list.
|
|
|
Back to Top
|
In its September 2008 issue, FORTUNE included Genentech on its list of the fastest growing companies in the United States. FORTUNE's ranking gives equal weight to three factors: revenue growth rate, EPS growth rate and three-year annualized total return to investors. The overall rank is based on the sum of the three ranks.
|
|
|
Back to Top
|
In April 2006, Genentech was presented with the Annual Helix Award at the BIO 2006 international conference in Chicago. This is the third year Genenetech has received the award. The James D. Watson Helix Award is the highest award of excellence for the biotechnology industry. The award recognizes biotechnology companies that have distinguished themselves by setting a singular standard of corporate leadership as reflected in performance in three distinctive areas: scientific innovation, company growth and corporate citizenship.
|
|
|
Back to Top
|
In February 2006, Genentech ranked number one in the biotechnology sector on Institutional Investor Magazine's inaugural "America's Most Shareholder-Friendly Companies" list. The ranking was based on a survey in which more than a thousand portfolio managers and analysts in the U.S. and abroad were asked to name the companies in their areas of expertise that are the most attentive to shareholders. The survey instructed respondents to consider the quality of the companies' governance and their investor relations practices.
|
|
|
Back to Top
|
In July 2009, the San Francisco Business Times named Genentech number nine on its list of Top Bay Area Corporate Philanthropists at the annual Bay Area Corporate Philanthropy Summit and Awards. This is the third year Genentech has ranked number nine and the fourth consecutive year the company has appeared on the list.
|
|
|
Back to Top
|
In its Spring 2006 issue, Business Ethics magazine named Genentech to its annual list of "100 Best Corporate Citizens." This is the second year in a row that Genentech has made the list. The list, in its seventh year, is considered the standard bearer in corporate social responsibility circles. It evaluates the 1,000 largest public companies traded in the U.S. along eight categories: shareholders, community, governance, diversity, employees, environment, human rights and product.
|
|
|
Back to Top
|
In April 2009, Genentech's chairman and CEO Arthur D. Levinson, Ph.D., was named to Institutional Investor magazine's "America's Best CEOs" List. Arthur Levinson ranked number two CEO in Biotechnology, a sub-category of the Healthcare category. Rankings are determined by a survey of buy-side analysts, portfolio managers and other investment professionals. Respondents were asked to name the best U.S. CEOs in the sectors in which they invest. This is the second year that Arthur Levinson has ranked number two in the Biotechnoloy category.
|
|
|
Back to Top
|
In March 2009, Genentech's chairman and CEO Arthur D. Levinson, Ph.D., was named to Barron's magazine's list of 30 "World's Best CEOs." The list of 30 top corporate leaders from around the world is based on an analysis of profit growth during a CEO's tenure, stock-price gains, leadership strength and industry stature. Barron's seeks CEOs who've made a difference to their organizations and who would be missed by investors if they departed. This is the second time Arthur Levinson has appeared on the list.
|
|
|
Back to Top
|
In its January 2007 issue, Institutional Investor magazine named Genentech's chairman and Chief Executive Officer Arthur D. Levinson, Ph.D., number one in the biotechnology category on its "Most Noteworthy CEOs" list. The ranking is determined based on the responses of research analysts and portfolio managers to the question, "Who do you regard as the best CEO in the sector for which you're responsible?" This the second year in a row that Levinson has placed first on the list in the biotechnology category.
|
|
|
Back to Top
|
In its October 2008 issue, FORTUNE named Susan Desmond-Hellmann, president of Product Development at Genentech, one of the 50 most powerful women in American business. Ranked number 13, Desmond-Hellmann appears on the list for the seventh time. The key criteria FORTUNE uses in assembling its annual list are: the revenues and profits the woman controls; the importance of the business in the global economy; the arc of her career (where she's been and where she's likely to head); and her impact on culture and society.
|
|
|
Back to Top
|
In its November 29, 2006 issue, The Wall Street Journal ranked Dr. Susan Desmond-Hellmann, President of Product Development at Genentech, number 36 on its list of "50 Women to Watch 2006." The second-highest ranking official at the company, she was recognized for her success in managing drug development at Genentech. With her oversight, Genentech has successfully received multiple regulatory approvals from the U.S. Food and Drug Administration. Dr. Desmond-Hellmann also appeared on the newspaper's 2005 "50 Women to Watch" list. |
|
|
Back to Top
|
In its December 22, 2006 issue, Science magazine included Genentech's Lucentis® (ranibizumab injection) on its list of Top 10 Breakthroughs of 2006. Lucentis was included on the list after results from two clinical trials published in the New England Journal of Medicine in 2006 presented it as a promising treatment for age-related macular degeneration.
|
|
|
Back to Top
|
In 2006, Napoleone Ferrara, M.D., Fellow at Genentech, was elected to the Academy in recognition of his immense contributions to the field of angiogenesis, including his seminal discovery of VEGF. Genentech co-founder Herb Boyer was elected to the Academy in 1985; Executive Vice President of Genentech Research & Early Development Richard H. Scheller has been a member since 2000; and Marc Tessier-Lavigne, Executive Vice President of Research and Chief Scientific Officer at Genentech, was elected member of the Academy in 2005.
|
|
|
Back to Top
|
In June 2006, through its General Motors Cancer Research Awards (GMCRA) program, General Motors Foundation recognized Napoleone Ferrara, M.D., Genentech Fellow, for his seminal contribution to cancer research. His work has laid the foundation for validating the concept of anti-angiogenic therapy in cancer, which inhibits the growth of new blood vessels. The GMCRA program has previously awarded nearly $15 million to 108 scientists in an effort to focus worldwide attention on cancer research.
|
|
|
Back to Top
